Clinical Implications of Genetic Testing in Hypertrophic Cardiomyopathy
-
- Putting a clinical spotlight on HCM case studies
- Clinical Management of Hypertrophic Cardiomyopathy
- Improving Clinical Recognition of HCM
- Sudden Cardiac Death Prevention in HCM: Where Do We Stand in 2021?
- Imaging for the Diagnosis and Management of HCM
- Clinical Implications of Genetic Testing in HCM
- HCM: An Introduction and Overview
-
- Putting a clinical spotlight on HCM case studies
- Clinical Management of Hypertrophic Cardiomyopathy
- Improving Clinical Recognition of HCM
- Sudden Cardiac Death Prevention in HCM: Where Do We Stand in 2021?
- Imaging for the Diagnosis and Management of HCM
- Clinical Implications of Genetic Testing in HCM
- HCM: An Introduction and Overview
Clinical Implications of Genetic Testing in Hypertrophic Cardiomyopathy
Presenters: Dr. Anjali Owens, Dr. Sharon Cresci
Moderator: Dr. James Udelson
Summary: It is estimated that 1 in every 500 adults living in the U.S. have HCM, but a large percentage of patients are undiagnosed. Which of your patients is undiagnosed? Hypertrophic Cardiomyopathy (HCM) is the most common form of genetic heart disease and can affect people of any age. HCM can be a debilitating and life-changing disease. People with HCM are often forced to make lifestyle changes, such as limiting their activity, to accommodate their disease. Sometimes this accommodation might not even be noticed by the patient themselves meaning careful questioning of symptoms and changes in activity are critical.
Learn more about HCM in this free webinar so you are better able to discuss its impact with your patients.
Anjali Tiku Owens, MD
Assistant Professor of Medicine
University of Pennsylvania
Sharon Cresci, MD, FAHA, FACC, FASE
Washington University, Cardiovascular Division
Associate Professor of Medicine
Associate Professor of Genetics
Dr. James E. Udelson, MD, FAHA
Chief, Division of Cardiology,
Tufts Medical Center